Systematic review / meta-analysis / 2023
Adding Astragalus membranaceus to supportive care or immunosuppressive therapy improved remission and kidney markers in idiopathic membranous nephropathy.
A meta-analysis of 50 randomized controlled trials including 3,423 participants evaluated Astragalus membranaceus combined with supportive care or immunosuppressive therapy for moderate-to-high risk idiopathic membranous nephropathy. Compared to supportive care or immunosuppressive therapy alone, the combination significantly improved 24-hour urinary total protein (MD = -1.05, 95% CI [-1.21, -0.89], P = .000), serum albumin (MD = 3.75, 95% CI [3.01, 4.49], P = .000), serum creatinine (MD = -6.24, 95% CI [-9.85, -2.63], P = .0007), complete remission rate (RR = 1.63, 95% CI [1.46, 1.81], P = .000), and partial remission rate (RR = 1.13, 95% CI [1.05, 1.20], P = .0004). The authors noted that the included studies had inherent limitations, warranting future well-designed trials.
- Study type
- Systematic review and cumulative meta-analysis of RCTs
- Who was studied
- 3,423 participants with moderate-high risk idiopathic membranous nephropathy across 50 studies
- What was measured
- 24-hour urinary total protein, serum albumin, serum creatinine, complete remission rate, and partial remission rate
THE PAPER
Astragalus membranaceus formula for moderate-high risk idiopathic membranous nephropathy: A meta-analysis.
Wang D, Wang L, Zhang M, Li P, Zhang Q, Bao K. Medicine (Baltimore), 2023.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.